open access

Vol 49, No 4 (2011)
ORIGINAL PAPERS
Published online: 2012-01-16
Submitted: 2012-01-16
Get Citation

The prognostic significance of the immunohistochemical expression of P53 and BCL-2 in endometrial cancer

Bozena Dobrzycka, Slawomir J. Terlikowski, Magdalena Garbowicz, Jacek Niklinski, Lech Chyczewski, Marek Kulikowski
DOI: 10.5603/FHC.2011.0086
·
Folia Histochem Cytobiol 2011;49(4):631-635.

open access

Vol 49, No 4 (2011)
ORIGINAL PAPERS
Published online: 2012-01-16
Submitted: 2012-01-16

Abstract

The objective of this study was to verify the frequency of P53 and BCL-2 immunohistochemical expression in 98 patients with endometrial carcinoma, and to correlate it with clinical stage and patient survival. A significant difference was found regarding the frequency of P53 expression when comparing type I and II tumors (23.7% and 54.5%, respectively; p = 0.006). A positive correlation was observed between P53 immunoexpression and patient survival in type I and II tumors (p = 0.009 and p = 0.036, respectively). BCL-2 expression was significantly more frequent in early clinical stages in both types of endometrial cancer (p < 0.001 and 0.002) and correlated with a decrease in overall survival in type I endometrial cancer (p = 0.014). Thus, the prognostic value of these biomarkers in endometrial cancer needs to be further investigated. (Folia Histochemica et Cytobiologica 2011; Vol. 49, No. 4, pp. 631–635)

Abstract

The objective of this study was to verify the frequency of P53 and BCL-2 immunohistochemical expression in 98 patients with endometrial carcinoma, and to correlate it with clinical stage and patient survival. A significant difference was found regarding the frequency of P53 expression when comparing type I and II tumors (23.7% and 54.5%, respectively; p = 0.006). A positive correlation was observed between P53 immunoexpression and patient survival in type I and II tumors (p = 0.009 and p = 0.036, respectively). BCL-2 expression was significantly more frequent in early clinical stages in both types of endometrial cancer (p < 0.001 and 0.002) and correlated with a decrease in overall survival in type I endometrial cancer (p = 0.014). Thus, the prognostic value of these biomarkers in endometrial cancer needs to be further investigated. (Folia Histochemica et Cytobiologica 2011; Vol. 49, No. 4, pp. 631–635)
Get Citation

Keywords

endometrial cancer; P53; BCL-2; prognosis

About this article
Title

The prognostic significance of the immunohistochemical expression of P53 and BCL-2 in endometrial cancer

Journal

Folia Histochemica et Cytobiologica

Issue

Vol 49, No 4 (2011)

Pages

631-635

Published online

2012-01-16

DOI

10.5603/FHC.2011.0086

Bibliographic record

Folia Histochem Cytobiol 2011;49(4):631-635.

Keywords

endometrial cancer
P53
BCL-2
prognosis

Authors

Bozena Dobrzycka
Slawomir J. Terlikowski
Magdalena Garbowicz
Jacek Niklinski
Lech Chyczewski
Marek Kulikowski

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl